Evaluation of the effectiveness of curcumin in improving the symptoms of patients with chronic coronary syndrome

Phase 3

Not yet recruiting

• Conditions: Chronic coronary syndrome.; Chronic ischemic heart disease

• Registration Number: IRCT20150721023282N25
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Age above 18 years
Suffering from chronic coronary syndrome according to the guidelines of the European Society of Cardiology (ESC) published in 2019
Full consent to participate in the study

Exclusion Criteria

Using any product containing curcumin and turmeric during the last weekcontent_copyshare
History of acute coronary syndrome in the last 6 months
Suffering from any other heart disorders including myocarditis, cardiomyopathy and severe valvular disorder
Having hyperthyroidism
Having kidney failure (creatinine clearance less than 60 ml/min)
Liver disorder (Child-pugh score stage B or C)
Using psychoactive drugs (alcohol, marijuana, opioids, cocaine, dextroamphetamine)
The use of any anti-inflammatory or antioxidant drug (corticosteroid, NSAID, vitamins C or E, coenzyme Q10 products, immunosuppressive drugs, ...) from one week before the start of the intervention
Suffering from other cognitive disorders
History of allergy to curcumin
Difficulty hearing or speaking
pregnancy
breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum levels of cholesterol, LDL, HDL, TG, FBS, hs_CRP and uric acid and Changing the score of the SAQ questionnaire. Timepoint: Before and after the end of the intervention. Method of measurement: Seattle Angina Questionnaire (SAQ) and checking biomarkers of cholesterol, LDL, HDL, TG, FBS, hs_CRP and uric acid in blood samples.